# Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic Stroke

> **NCT01869478** · PHASE2 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 1 (actual)

## Conditions studied

- Stroke
- Ischemic Stroke

## Interventions

- **DRUG:** Intravenous Thrombolysis
- **DEVICE:** Endovascular Arterial Reperfusion

## Key facts

- **NCT ID:** NCT01869478
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Poor recruitment
- **Last updated:** 2016-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01869478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01869478, "Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01869478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*